Sarepta Therapeutics Files 8-K on Financials
Ticker: SRPT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 873303
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Sarepta dropped an 8-K detailing financials - check it out.
AI Summary
Sarepta Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to its business operations.
Why It Matters
This 8-K filing provides investors with crucial updates on Sarepta Therapeutics' financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-14895 (identifier) — Commission File Number
- 93-0797222 (identifier) — IRS Employer Identification No.
- 215 First Street, Cambridge, Massachusetts 02142 (address) — Principal Business Address
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated January 13, 2025.
What is Sarepta Therapeutics, Inc.'s state of incorporation?
Sarepta Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Sarepta Therapeutics, Inc.?
The Commission File Number is 001-14895.
Where is Sarepta Therapeutics, Inc.'s principal business address?
The principal business address is 215 First Street, Suite 415, Cambridge, Massachusetts 02142.
Filing Stats: 982 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-01-13 12:25:31
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SRPT NASDAQ Glo
- $1.5 billion — audited) cash position of approximately $1.5 billion as of December 31, 2024, and that the C
- $1.79 billion — hat the Company generated approximately $1.79 billion in total net product revenue (unaudited
- $638 million — ded December 31, 2024 and approximately $638 million in total net product revenue (unaudited
- $254 million — ucts, which includes: (i) approximately $254 million in net product revenue (unaudited) in t
- $967 million — ded December 31, 2024 and approximately $967 million in net product revenue (unaudited) in t
- $384 million — rsen) Injection, and (ii) approximately $384 million in net product revenue (unaudited) in t
- $821 million — ded December 31, 2024 and approximately $821 million in net product revenue (unaudited) in t
Filing Documents
- d900352d8k.htm (8-K) — 28KB
- d900352dex991.htm (EX-99.1) — 33KB
- g900352g0113170840506.jpg (GRAPHIC) — 6KB
- 0001193125-25-005160.txt ( ) — 194KB
- srpt-20250113.xsd (EX-101.SCH) — 3KB
- srpt-20250113_lab.xml (EX-101.LAB) — 17KB
- srpt-20250113_pre.xml (EX-101.PRE) — 11KB
- d900352d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report contains forward looking statements. Any statements contained in this Current Report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "may," "intends," "prepares," "looks," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the Company's expected financial results. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the estimates and judgments the Company makes, or the assumptions on which it relies, in preparing its consolidated financial statements could prove inaccurate; the Company's revenues and operating results could fluctuate significantly, which may adversely affect the Company's stock price; and those risks identified under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 as well as other SEC filings made by the Company which you are encouraged to review. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 13, 2025 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: January 13, 2025 By: /s/ Douglas S. Ingram Douglas S. Ingram President and Chief Executive Officer